Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,489Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M14.1EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)23.4Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.610-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %1.8PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M14,500,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with IXJ

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

IXJ is held by these investors:

IXJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.48983.12view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94506.14view
Dinwoodie, Tyler Wayne PaulSenior Officer 2017-01-16Buy4,000$0.1760300view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.367450view
Bebek, IvanDirector 2017-01-16Buy8,990$3.382937.87view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.4124943.9view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91267.9view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.271537.64view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.3870.06view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1568353.33view

Quarterly/Annual Reports about IXJ:

    News about IXJ:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Johnson & Johnson’s Pharmaceuticals Segment Mar 14 2017
    How Gilead’s Other Products Fared in 2016 Mar 02 2017
    Strong Performance of AstraZeneca’s Brilinta and Farxiga in 2016 Feb 28 2017
    Pfizer’s Valuation after Its 4Q16 Earnings Release Feb 24 2017
    Eli Lilly & Co.’s Endocrine Franchise Feb 24 2017
    Analyzing Merck & Co.’s Revenue Estimates in 4Q16 Jan 31 2017
    Opdivo: Bristol-Myers Squibb’s Blockbuster Oncology Drug Jan 31 2017
    Exploring JNJ’s 2017 Profitability and Financial Guidance Jan 30 2017
    Johnson & Johnson’s 4Q16 Performance by Business Segment Jan 26 2017
    How Will Eli Lilly’s Neuroscience Franchise Fare in 4Q16? Jan 26 2017
    How Bristol-Myers Squibb’s Oncology Drug Performed in 4Q16 Jan 24 2017
    Novartis’s 4Q16 Estimates: How Could Sandoz Perform? Jan 23 2017
    Why Johnson & Johnson’s 4Q16 Revenues Could Grow Jan 20 2017
    The 'Trump Rally' in Stocks Is Ending -- Here's How You Can Profit Jan 12 2017
    Exploring GlaxoSmithKline’s Business Segments Dec 30 2016
    GlaxoSmithKline’s Revenue Trend Dec 29 2016
    How Does Johnson & Johnson’s Valuation Compare to Its Peers? Dec 09 2016
    Inside Merck’s Business Segment-Wise Performance Dec 01 2016
    Allergan’s Valuation Compared to Its Peers Nov 29 2016
    Inside Eli Lilly’s Neuroscience Franchise Nov 23 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)